Meeting
2011 ASCO Annual Meeting
Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.
Authors
Y. Y. Janjigian
Memorial Sloan-Kettering Cancer Center, New York, NY
Y. Y. Janjigian , H. J. Groen , L. Horn , E. F. Smit , Y. Fu , F. Wang , M. Shahidi , L. J. Denis , W. Pao , V. A. Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Metastatic/Non-small Cell
Track
Lung Cancer
Sub Track
Metastatic
Clinical Trial Registration Number
NCT01090011
Citation
J Clin Oncol 29: 2011 (suppl; abstr 7525^)
Abstract #
7525^
Poster Bd #
14
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes.
First Author: Alexandra Pender
Poster
2018 ASCO Annual Meeting
Pilot trial of epidermal growth factor (EGF) ointment for the patients with epidermal growth factor receptor (EGFR) inhibitor related skin side effects.
First Author: Sung Yong Oh
Poster
2017 ASCO Annual Meeting
Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study).
First Author: Akito Hata
Poster
2023 ASCO Quality Care Symposium
Stomatitis in patients receiving EGFR-targeted therapy for non-small cell lung cancer: A population-based cohort study across the United States.
First Author: Chuan Lu